DarioHealth Reports Revenue Dip Amid Strategic Pivot to ARR Growth — DarioHealth Corp.

Event summary

DarioHealth's 2025 revenue declined to $22.4M from $27.0M in 2024 due to a single legacy client loss from the Twill acquisition, offset by organic growth.
Fourth quarter 2025 revenues grew sequentially to $5.2M from $5.0M in Q3 2025, driven by new ARR contracts.
GAAP gross margins improved to 57% in 2025 from 49% in 2024, with non-GAAP gross margins sustaining at 80% for two years.
Operating expenses decreased by 28% year-over-year in Q4 2025, leading to a continued reduction in operating loss.
Pipeline of commercial opportunities grew to $122M as of December 31, 2025, based on 200+ B2B2C opportunities.

The big picture

DarioHealth's strategic shift towards building ARR revenues from its core B2B2C business, coupled with significant cost reductions, positions the company for sustained high growth. The company's ownership of the entire vertical value chain, including proprietary AI models and 13 billion real-world data points, provides a structural competitive advantage. As healthcare expenses continue to rise, digital health solutions like Dario's are becoming increasingly important for driving behavior change and delivering measurable clinical and financial results.

What we're watching

Revenue Growth Trajectory: How the conversion of $12.9M in contracted and late-stage ARR contracts into revenue in 2026 and 2027 will impact DarioHealth's growth trajectory.
Operational Efficiency: Whether DarioHealth can sustain its 28% year-over-year reduction in operating expenses and achieve cash flow breakeven by mid-2027.
Market Expansion: The pace at which DarioHealth can expand its musculoskeletal (MSK) product in international markets and leverage its channel partnerships to reach larger populations.